Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials.
Level 1 - systematic review of randomized trials
Meta-analysis of randomized controlled trials
PubMed 25440725 · doi:10.1016/j.mayocp.2014.08.021
What was done
Authors searched MEDLINE, Cochrane Library, Scopus, and EMBASE (November 1987 to May 2014) for randomized controlled trials examining the effects of coenzyme Q10 (CoQ10) supplementation on plasma creatine kinase (CK) activity and muscle pain in patients on statin therapy. Data extraction was conducted by two independent reviewers.
What was found
Six studies totaling 302 patients were included. CoQ10 supplementation had no significant effect on plasma CK activity across 5 studies (n=226; mean difference 11.69 U/L; 95% CI, -14.25 to 37.63; P=.38). It also showed no statistically significant reduction in muscle pain across 5 studies (n=253; standardized mean difference -0.53; 95% CI, -1.33 to 0.28; P=.20). Meta-regression revealed no dose-response relationship for plasma CK (slope -0.001; 95% CI, -0.004 to 0.001; P=.33) or muscle pain (slope 0.002; 95% CI, -0.005 to 0.010; P=.67).
Why it matters
CoQ10 is widely used and recommended off-label for statin-associated muscle symptoms, but pooled trial evidence does not demonstrate a measurable therapeutic benefit over placebo.
Limits
The total sample size across all included trials was small (302 total participants), resulting in wide confidence intervals for muscle pain relief. The abstract does not detail statin types, specific CoQ10 formulations, treatment durations, or baseline symptom severity.
Cited by
- supports Clinical trials evaluating ubiquinol or CoQ10 supplementation in statin users have shown no difference in reducing the incidence of statin-associated muscle soreness.